Cue Biopharma Sees Profitable Growth with $7.5M Milestone
Cue Biopharma will receive a $7.5 million preclinical milestone from Boehringer Ingelheim after BI selected the first compound from...
No videos found.
Nurix Announces Q1 2026 Financials & Corporate Update
Nurix Therapeutics is moving its BTK degrader, bexobrutideg, onto a registrational track in relapsed/refractory chronic lymphocytic leukemia with an...
Novabridge Announces Full Year 2025 Financial Results
NovaBridge Biosciences reported year-end 2025 results and advanced two mid-stage assets: givastomig, a CLDN18.2 x 4-1BB bispecific antibody in...
Europe’s Biotech Execution Gap Demands Capital Reform and Regulatory Harmony
At BIO-Europe Spring 2026 in Lisbon, investors and pharma executives diagnosed Europe's biotech bottleneck not as a science deficit...
The Semaglutide Patent Cliff Isn’t a Threat to Novo Nordisk — It’s a Threat to Everyone Who Thought Obesity Was a Premium Market
As semaglutide patents begin expiring and generic manufacturers in India and China gear up for mass production, the global...
NovaBridge Releases New Full Year 2025 Financial Results
NovaBridge Biosciences reported full-year 2025 results and set out a tighter, higher-stakes development agenda around two lead assets. In...
Coeptis Announces Successful Nasdaq Approval for Z Squared
Nasdaq has approved, subject to closing conditions, the listing of the post-merger company formed by Coeptis Therapeutics and Z...
Marvel Biosciences Secures New Investment for Future Growth
Marvel Biosciences has secured financial and strategic backing from 5 Horizons Ventures to initiate a Phase I study of...
AscellaHealth’s Surging Growth Earns Financial Times Honor
AscellaHealth has been named to the Financial Times’ Americas’ Fastest Growing Companies 2026 list for the fourth consecutive year,...
Avicanna Announces Important Changes to Board of Directors
Avicanna has announced a board transition effective April 1, 2026, with the resignation of John McVicar and the appointment...